Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors

A series of novel l-lysine derivatives were designed, synthesized, and assayed for their inhibitory activities on amino-peptidase N (APN)/CD13 and matrix metalloproteinase-2 (MMP-2). The preliminary biological test showed that most of the compounds displayed a high inhibitory activity against MMP-2 and a low activity against APN except compound B6 which exhibited good potency (IC50 = 13.2 μM) similar with APN inhibitor Bestatin (IC50=15.5 μM), and could be used as lead compound in the future.

From the docking results and energy analysis, we found the pharmacophoric conformation of B6 (Bestatin in the X-ray crystal is showed in green).Figure optionsDownload as PowerPoint slide